[Administration of afobasol for correction of mental disorders in celiac disease patients].
OBJECTIVE
To study afobasol efficacy in anxiety and neurotization correction in patients with celiac disease (CD).


METHODS
We examined 17 CD patients with mental diseases (anxiety, anxiophobic and neurotic disorders) aged 35.3 +/- 3.5 years. Personal and situational anxiety levels were assessed with multivariate questionnaire of the integrative anxiety test, neurotization--with Wasserman's questionnaire. Mental diseases were treated for 4 weeks with afobasol in a daily dose 30 mg.


RESULTS
An initial level of personal anxiety was elevated in 100% patients, of situational anxiety--in 66.7%. These kinds of anxiety (most of all general, emotional discomfort, asthenic and phobic components) were treated with a positive effect. Neurotization was high in 11 patients. The treatment was effective in 6 of them. Side effects were not noted. The highest reduction was seen in emotional discomfort, asthenic component and anxiety.


CONCLUSIONS
Afobasol is effective in management of mental diseases in patients with celiac disease.
Oreshko
L S
LS
D000328:Adult; D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D001562:Benzimidazoles / Q000627:therapeutic use*; D002446:Celiac Disease / Q000453:epidemiology*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D009025:Morpholines / Q000627:therapeutic use*; D010698:Phobic Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D011581:Psychological Tests; D012720:Severity of Illness Index
C410924:2-((2-morpholino)ethylthio)-5-ethoxybenzimidazole; D001562:Benzimidazoles; D009025:Morpholines